Provider review
Direct Meds review
Sublingual drops beside injections, with nothing billed alongside the medication.
A needle-free route for both molecules and no separate membership — against pricing nobody has verified live.
Price as published
Compounded semaglutide ~$179/mo sublingual, ~$297/mo injectable · tirzepatide ~$224/mo sublingual, ~$399/mo injectable · promo pricing ~$147 (company-stated)
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
The verdict
Direct Meds pairs the thing this audience actually needs — sublingual drops, in which a fraction of a dose is a practical thing to take — with all-inclusive pricing and no membership stacked underneath, for both molecules. The problem is provenance. The published figures come from the company's own press release rather than a live checkout, the brand appears across several domains, and the states it serves are not disclosed. Treat every number as provisional and confirm the current offer directly before you start.
The trade-off we would want you to read first
Pricing is company-stated (press release), not live-verified, so treat the figures as provisional
Who it suits, and who it does not
A good fit if
- You want a sublingual route and want the injectable available from the same provider
- You want no membership billed beside the medication
- You are comfortable confirming the current offer yourself before ordering
Look elsewhere if
- You want figures verified on a live checkout rather than a company statement
- You want a single unambiguous operator rather than a brand spread across domains
- You need published state availability before starting
How the programme works
Direct Meds launched in 2024 as a compounded-only GLP-1 program and stands out for offering oral/sublingual drops alongside standard injectables — a format most competitors do not carry. Pricing is all-inclusive with no separate membership: roughly $179/mo for sublingual semaglutide and $297/mo injectable, with tirzepatide around $224/$399, plus promotional pricing near $147. Both molecules are available. The figures come from the company's own press release rather than a live, verifiable checkout, and the brand appears across multiple domains, so confirm the current offer directly before starting.
At a glance
- Pricing structure
- Varies by dose, plan or tier
- Consult
- Included in the price
- Compounding
- Not publicly identified
- Labs
- Optional
- Dietitian support
- Not included
Strengths
- Rare oral/sublingual GLP-1 drops in addition to injectables — a real option for needle-averse patients
- All-inclusive pricing with no separate membership stacked on the medication
- Both semaglutide and tirzepatide available
The other trade-offs
- Compounded-only, and compounded GLP-1s are not FDA-approved
- A newer, somewhat ambiguous operator spread across multiple domains
- The states it serves are not disclosed, and non-injectable GLP-1 absorption is poorly evidenced
Before you buy
Intentional GLP-1 microdosing is off-label and unproven — no randomised trial has established that a sub-label dose does anything, and any dose belongs with a clinician who knows your history. If you are going to have that conversation, have it with real numbers.
Where this sits on the board
Direct Meds is one of 24 low-dose GLP-1 providers we track. The board lists every published price on one screen, ordered with the companies that pay us first — a mechanism we state there, on the page it applies to.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
Funding & disclosures
- A number of links are affiliate or referral links.
- Begin treatment through one and we may earn a commission via the Katalys network — at no added cost to you.
- What we write about a provider is the same either way — unflattering findings about one that pays us stay in.
- Full detail: disclosure page.